/

Società

Ja

Non verificato

Jaguar Gene Therapy, LLC

Di cosa scriviamo

BiotecnologiaIndustriaMedicina - VarieSaluteSanità

2 comunicati stampa

Guarda tutti i comunicati

24/02/2026

Industria

Salute

Biotecnologia

Sanità

Medicina - Varie

Jaguar Gene Therapy Announces Successful Completion of Dosing of First Patient Cohort in Clinical Trial Evaluating JAG201 for the Treatment of a Leading Monogenic Cause of Autism Spectrum Disorder Known as Phelan-McDermid Syndrome

Fonte

Jaguar Gene Therapy, LLC

Emittente

1.00

0

09/07/2024

Scienza

Igiene alimentare

Biotecnologia

Medicina - Varie

Sanità

Farmaceutica

Salute

Jaguar Gene Therapy to Initiate Inaugural Pediatric Clinical Trial Targeting a Genetic Form of Autism Spectrum Disorder and Phelan-McDermid Syndrome

Fonte

Jaguar Gene Therapy, LLC

Emittente

1.00

0

Seguaci

0

Compatibilità

0